Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124692 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles
A NA study of Cheek Wrinkles, sponsored by Galderma R&D.
- Completed
- Registry status
- NA
- Development phase
- 149
- Enrollment target
- 13
- Study locations
NCT04124692: Completed NA study of Cheek Wrinkles, sponsored by Galderma R&D.
NCT04124692 is a NA study of Cheek Wrinkles that has completed, run by Galderma R&D. The registered enrollment target is 149 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04124692, a NA study of Cheek Wrinkles, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- NA
- Development phase
- 149 participants
- Enrollment target
- 13
- Study locations
Study Summary
The study has been designed to evaluate the safety and effectiveness of Sculptra Aesthetic as a single regimen for correction of cheek wrinkles after changes in reconstitution and injection procedures compared to the approved label.
Primary Outcome
Responder rate was defined as the percentage of participants with at least a 1-grade improvement from baseline on the GCWS, on both sides of the face, concurrently. GCWS is a validated 5-point scale used to assess the severity of cheek wrinkles: 0 (none \[no lines or wrinkles\]), 1 (mild \[only few superficial lines\]), 2 (moderate \[many superficial lines or a few shallow wrinkles\]), 3 (severe \[many shallow wrinkles or a few moderate depth wrinkles\]) and 4 (very severe \[many moderate wrinkl
Conditions Studied
Interventions
- DEVICE Sculptra Aesthetic new dilution
Study Locations (13)
California
- Galderma Research Site - Encino
- Galderma Research Site - Redondo Beach
- Galderma Research Site - San Diego
New York
- Galderma Research Site - New York
- Galderma Research Site - New York
Texas
- Galderma Research Site - Dallas
- Galderma Research Site - Spring
Arizona
- Galderma Research Site - Scottsdale
District of Columbia
- Galderma Research Site - Washington D.C.
Florida
- Galderma Research Site - Coral Gables
Georgia
- Galderma Research Site - Alpharetta
Louisiana
- Galderma Research Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2021-08-12 |
| Phase | NA |
What the finished NCT04124692 record still lists
NCT04124692 is an interventional study that assigns participants to a tested intervention. The registered 149 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cheek Wrinkles appearing as the primary indexed condition, and to 1 intervention - of which Sculptra Aesthetic new dilution is the first listed.
NCT04124692 lists 13 locations in 9 states (California, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT04124692 about?
NCT04124692 is a clinical study titled "Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles". The study has been designed to evaluate the safety and effectiveness of Sculptra Aesthetic as a single regimen for correction of cheek wrinkles after changes in reconstitution and injection procedures compared to the approved label.
What is the current status of trial NCT04124692?
This trial is currently completed. It is a NA study. The enrollment target is 149 participants. The study started on 2019-11-12. Estimated completion is 2021-08-12.
What conditions does trial NCT04124692 study?
This clinical trial studies the following conditions: Cheek Wrinkles.
What interventions are being tested in trial NCT04124692?
The interventions under investigation include: Sculptra Aesthetic new dilution (DEVICE).
Who is sponsoring clinical trial NCT04124692?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04124692 being conducted?
This trial has 13 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cheek Wrinkles
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04124692's enrollment target sits among peer trials
149 702nd of 2000 higher than 1,299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04188535 · 149 participants · NA
Serial MRI Scans During Radiation Therapy
- NCT05828511 · 149 participants · Phase 1
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI